200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 137159-92-3
137159-92-3 | Guanidine, N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-
CAS No: 137159-92-3 Catalog No: AG0012VJ MDL No:
Product Description
Catalog Number:
AG0012VJ
Chemical Name:
Guanidine, N-(3-ethylphenyl)-N-methyl-N'-1-naphthalenyl-
CAS Number:
137159-92-3
Molecular Formula:
C20H21N3
Molecular Weight:
303.4008
IUPAC Name:
1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine
InChI:
InChI=1S/C20H21N3/c1-3-15-8-6-11-17(14-15)23(2)20(21)22-19-13-7-10-16-9-4-5-12-18(16)19/h4-14H,3H2,1-2H3,(H2,21,22)
InChI Key:
BFNCJMURTMZBTE-UHFFFAOYSA-N
SMILES:
CCc1cccc(c1)N(C(=N)Nc1cccc2c1cccc2)C
UNII:
46475LV84I
Properties
Complexity:
406
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
303.174g/mol
Formal Charge:
0
Heavy Atom Count:
23
Hydrogen Bond Acceptor Count:
1
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
303.409g/mol
Monoisotopic Mass:
303.174g/mol
Rotatable Bond Count:
4
Topological Polar Surface Area:
41.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.6
Literature
| Title | Journal |
|---|---|
| Prediction of outcome after moderate and severe traumatic brain injury: external validation of the International Mission on Prognosis and Analysis of Clinical Trials (IMPACT) and Corticoid Randomisation After Significant Head injury (CRASH) prognostic models. | Critical care medicine 20120501 |
| Pathophysiology, treatment, and animal and cellular models of human ischemic stroke. | Molecular neurodegeneration 20110101 |
| Caffeinol at the receptor level: anti-ischemic effect of N-methyl-D-aspartate receptor blockade is potentiated by caffeine. | Stroke 20100201 |
| Catalpol increases brain angiogenesis and up-regulates VEGF and EPO in the rat after permanent middle cerebral artery occlusion. | International journal of biological sciences 20100101 |
| The rise and fall of NMDA antagonists for ischemic stroke. | Current molecular medicine 20040301 |
| Inhibition of human alpha 7 nicotinic acetylcholine receptors by open channel blockers of N-methyl-D-aspartate receptors. | British journal of pharmacology 20031201 |
| Excitatory amino acid antagonists for acute stroke. | The Cochrane database of systematic reviews 20030101 |
| Why did NMDA receptor antagonists fail clinical trials for stroke and traumatic brain injury? | The Lancet. Neurology 20021001 |
| Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells. | The Journal of biological chemistry 20020419 |
| Patient safety in trials of therapy for acute ischemic stroke. | JAMA 20020227 |
| Neuroprotective agents in acute ischemic stroke. | The Journal of the Association of Physicians of India 20020201 |
| Future of neuroprotective drugs in doubt. | Nature medicine 20020101 |
| Glutamate AMPA receptor antagonist treatment for ischaemic stroke. | Current medical research and opinion 20020101 |
| Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial. | JAMA 20011205 |
| Ensuring patient safety in clinical trials for treatment of acute stroke. | JAMA 20011205 |
| Effects of cerestat and NBQX on functional and morphological outcomes in rat focal cerebral ischemia. | Pharmacology, biochemistry, and behavior 20010301 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.